AzTrials
AzTrials

Supraglottic Airway DeviceNCT06058481

Comparing the Clinical Performance of BlockBuster vs Proseal-LMA in Unparalysed Patients Undergoing General Anesthesia

A study testing Blockbuster and Proseal-LMA in people with Supraglottic Airway Device, run by Universiti Kebangsaan Malaysia Medical Centre at 1 site in Malaysia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Patients aged 19 to 78 years with ASA status I-II scheduled for elective surgery under general anesthesia, were recruited and randomized into two groups, Group A (BlockBuster) and Group B (Proseal-LMA). Anesthesia induction for both groups was standardized with no paralysis given. Read more about this study

Who is it for?
Ages 18 to 80 yearsHealthy volunteers can take part
Conditions the study is for
Supraglottic Airway Device
What is being tested?
Blockbuster and Proseal-LMA
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteMalaysia
Study dates
31 Jul 2019to 31 Jul 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • age range of 19 to 78 years
  • classified as American Society of Anesthesiologists Physical Status (ASA) class I or II
  • underwent elective surgery under general anesthesia that required supraglottic airway insertion.

Who cannot join

  • patients with a body mass index (BMI) over 35 kg/m2.
  • patients with limited mouth opening of less than two finger breath of inter-dental gap, edentulous, loose teeth and airway abnormalities.
  • patients who at risk of aspiration.
  • patients with known allergies to fentanyl and propofol.

Trial locations and contacts

1 site in 1 country.

Malaysia1 site
  • Hospital Canselor Tuanku Muhriz Universiti Kebangsaan Malaysia

    Cheras, Kuala Lumpur, 56000

Other trials in Malaysia

About this study

Patients aged 19 to 78 years with ASA status I-II scheduled for elective surgery under general anesthesia, were recruited and randomized into two groups, Group A (BlockBuster) and Group B (Proseal-LMA). Anesthesia induction for both groups was standardized with no paralysis given. Supraglottic airway (SGA) insertion (either Blockbuster or Proseal-LMA) was executed by a single experienced investigator. The investigator inserted the BlockBuster in Group A patients and the Proseal-LMA in Group B patients. These parameters were compared between the groups; the number of attempts, time taken to achieve successful insertion, oropharyngeal leak pressure (OLP), fiberoptic view of SGA position, hemodynamics changes and complications from the insertion.

Read the detailed description

This prospective, randomised single-blinded study, was conducted at the operation theatre of Universiti Kebangsaan Malaysia Medical Centre (UKMMC), following approval from the Institutional Ethics Committee of Universiti Kebangsaan Malaysia (UKM). The recruited patients were within the age range of 19 to 78 years, classified as American Society of Anesthesiologists Physical Status (ASA) class I or II, and underwent elective surgery under general anesthesia that required supraglottic airway (SGA) insertion. Exclusion criteria included a body mass index (BMI) over 35 kg/m2, limited mouth opening of less than two finger breath of inter-dental gap, edentulous, loose teeth, airway abnormalities, risk of aspiration, and known allergies to fentanyl and propofol.

During the pre-operative visit, patients were briefed about the study, and written informed consent was obtained. All recruited patients were fasted for at least 6 hours before the scheduled operation. No premedication was administered. Patients were then randomly assigned to either Group A (Blockbuster) or Group B (Proseal-LMA) using simple randomisation. SGA insertion was performed by a single operator with more than five years of experience using the Proseal-LMA and had received training using Blockbuster on a mannequin and successfully inserted it in 20 patients .

In the operation theatre, minimal standard monitoring was applied and followed by preoxygenation for three minutes. Anesthesia induction was conducted using intravenous (IV) fentanyl of 2 mcg/kg and IV propofol of 2 to 2.5 mg/kg. Additional propofol boluses of 10 to 20 mg were administered if anesthesia was inadequate and the doses were documented. Neuromuscular relaxant was not used. After achieving unconsciousness, mask ventilation was initiated with an oxygen and sevoflurane mixture until a Minimum Alveolar Concentration (MAC) of 1.3 was achieved. The depth of anesthesia was assessed by pupillary size and jaw relaxation prior to SGA insertion. The appropriate size of the SGA was chosen based on the manufacturer's recommendation according to the patient's body weight. Before SGA insertion, lubrication was applied to the outer cuff with a water-based lubricant and the cuff was fully deflated.

An assigned assistant recorded the number of attempts and time taken for successful insertion. The time taken for SGA insertion was measured from the moment SGA passes the patient's front incisor until the appearance of the first end-tidal CO2 (ETCO2) waveform on the capnography. The measurement of time was stopped and reset for subsequent attempts. The investigator inserted the BlockBuster in Group A patients and the Proseal-LMA in Group B patients. The Proseal-LMA is a reusable device and the items that used in this study was used less than 10 times previously. After SGA insertion, the cuff was inflated to a pressure of 60 cmH2O using a cuff pressure manometer. Successful insertion was determined by these three findings: chest expansion, no audible leak detected during manual bagging and the appearance of square wave capnograph tracing with ventilation generating expiratory tidal volumes of 6 to 8 ml/kg with an oxygen flow of 6 litre/min, adjustable pressure-limiting (APL) valve closed at 30 cmH2O. An audible leak was determined by listening at the mouth or lateral thyroid cartilage using a stethoscope for audible noise.

Following successful SGA insertion, a gastric tube sized 12 or 14 Fr was inserted. Oropharyngeal leak pressure (OLP) was assessed by setting the APL valve of the circle system at 30 cmH2O with a fresh gas flow of 3L/min. The OLP was determined by observing the airway pressure at equilibrium until an audible noise was heard over the mouth with a stethoscope. For safety reasons, the OLP was kept below 40 cmH2O and pressure was recorded.

The removal of SGA from the oral cavity was considered a failed attempt. If there was a failure of insertion or failure of placement of SGA (inadequate chest expansion, inability to generate adequate tidal volume or audible leak), the patient was ventilated again with 100% oxygen and 3% sevoflurane to maintain SpO2 above 95% before the next attempt. If inappropriate SGA size due to a large leak (small size) or difficult insertion (large size), new SGA insertion with different sizes was allowed once in this study. A maximum of three attempts was allowed, after which the patient was considered as failed SGA insertion. The subsequent airway management was determined by the responsible anaesthesiologist. The patient was dropped out of this study and excluded from the analysis if failed SGA insertion after three attempts and surgery duration exceeding two hours.

Anesthesia was maintained with sevoflurane in an air-oxygen mixture and ventilation was adjusted to achieve an adequate tidal volume of 6 to 8 ml/kg. Blood pressure, mean arterial pressure (MAP), heart rate (HR), ETCO2 and saturation were recorded at pre-induction, during induction, as well as at 5 and 10 minutes after SGA insertion. The position of SGA after insertion in relation to the laryngeal inlet was verified using an intubating bronchoscope Ambu aScope 4 Broncho Regular Endoscope (Ambu A/S, Denmark) with a working channel width of 2.2mm. The laryngeal view obtained was scored according to Keller et al. grading system: Grade 4, only vocal cords visible; Grade 3, vocal cords plus posterior epiglottis visible; Grade 2, vocal cords plus anterior epiglottis visible; Grade 1, vocal cords not visible.

The presence of airway complications related to SGA insertion such as laryngospasm, bronchospasm, gagging, coughing and aspiration was recorded and managed by the responsible anaesthesiologist. At the end of the operation, sevoflurane was discontinued, and the patient was allowed to breathe spontaneously in 100% oxygen. The SGA was removed once the patient had regained consciousness, was responsive to verbal commands and was able to breathe spontaneously generating tidal volumes of at least 6 to 8 ml/kg. Following SGA removal, the device was checked for blood-stained secretion and documented. The duration of anesthesia was recorded and was defined as the time taken from anesthesia induction until SGA removal. Patients were evaluated for the incidence of sore throat in the recovery area and at 24 hours post-anesthesia.

Being tested
Blockbuster, Proseal-LMA

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BlockbusterDevice

    The investigator inserted the BlockBuster in Group A patients.

  • Proseal-LMADevice

    The investigator inserted the Proseal-LMA in Group B patients.

Study groups in NCT06058481
Study groupRoleWhat they receive
Group AExperimentalThe investigator inserted the BlockBuster (supraglottic airway device) in Group A patients after induction of anaesthesia.
Receives: Device: Blockbuster
Group BActive comparatorThe investigator inserted the Proseal-LMA (supraglottic airway device) in Group B patients after induction of anaesthesia.
Receives: Device: Proseal-LMA

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Oropharyngeal leak pressure measurement to assess efficacy of airway seal by the supraglottic airway device

    Oropharyngeal leak pressure (OLP) was assessed by setting the adjustable pressure-limiting (APL) valve of the circle system at 30 cmH2O with a fresh gas flow of 3L/min. The OLP was determined by observing the airway pressure at equilibrium until an audible noise was heard over the mouth with a stethoscope. The measurement unit is cmH2O. For safety reasons, the OLP was kept below 40 cmH2O.

    Measured: 1 year

Secondary outcomes (3)
  1. First pass success rate

    Number of patients who successfully being inserted with the supraglottic device on the first attempt

    Measured: 1 year

  2. Number of supraglottic airway insertion attempt

    Number of supraglottic airway insertion attempt in each patients

    Measured: 1 year

  3. Supraglottic airway insertion time

    Supraglottic airway (SGA) insertion time was measured from the moment SGA passes the patient's front incisor until the appearance of the first end-tidal CO2 waveform on the capnography. The measurement unit is seconds.

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Sep 2023
  2. Study start31 Jul 2019
  3. Primary completion31 Jul 2020
  4. Study completion31 Jul 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
100 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06058481
Sponsor's protocol ID
FF-2019-365
Other IDs
Fundamental data
Status last verified
Sep 2023
First submitted
12 Sep 2023
Last updated
28 Sep 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Blockbuster and Proseal-LMA in people with Supraglottic Airway Device, run by Universiti Kebangsaan Malaysia Medical Centre at 1 site in Malaysia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Malaysia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Oropharyngeal leak pressure measurement to assess efficacy of airway seal by the supraglottic airway device (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in